title: [Fluconazole and treatment of onychomycosis. About 86 cases].
abstract: Systemic treatment of onychomycosis is based these last years on the new drug utilization aiming to decrease the length of the treatment and secondary effects particularly with fluconazole. The aim of our study is to determine the efficiency and the tolerance of the fluconazole (Funzol) managed to the dose of 150 mg per week in the treatment of onychomycosis. It is a multicentric and prospective study done to different department of dermatology in Tunisia. Are included adult patients with clinical and mycologic documented onychomycosis. They are treated during 12 to 24 weeks for the fingernail and 24 to 36 weeks for the toenail. The assessment of the efficiency and the tolerance of the drug was clinic and biologic. During this survey, 86 patients are included, 55 female and 31 male with mean age of 43.5 years. Onychomycosis seat to hands in 30 cases (34.8%) with a predominance of Candida species (73%), to toes in 68 cases (79%) witch due in 85% of cases to dermatophytic agent (85%). At 6 months, clinical cure rate is observed in 51% of cases. After 9 months, at the end of therapy, 84% of patients were judged clinical successes and culture was negative in 82% of cases. Some minimal secondary effects are signalled in 11% of cases to 6 weeks and 10% to 12 weeks not justifying the stop of the treatment. So this study confirms the efficiency and the good tolerance of fluconazole in the treatment of onychomycosis.
authors.affiliation: Service de Dermatologie, Hôpital La Rabta, Tunis.
authors.forename: Dalenda
authors.initials: D
authors.lastname: El Euch
authors.forename: Samir
authors.initials: S
authors.lastname: Bouassida
authors.forename: Monia
authors.initials: M
authors.lastname: Kourda
authors.forename: Nedia
authors.initials: N
authors.lastname: Ezzine
authors.forename: Mohamed
authors.initials: M
authors.lastname: Denguezli
authors.forename: Inçaf
authors.initials: I
authors.lastname: Mokhtar
authors.forename: Nejib
authors.initials: N
authors.lastname: Doss
authors.forename: Hamida
authors.initials: H
authors.lastname: Turki
authors.forename: Mohamed
authors.initials: M
authors.lastname: Ridha Kamoun
authors.forename: Rafia
authors.initials: R
authors.lastname: Nouira
authors.forename: Amel
authors.initials: A
authors.lastname: Ben Osman Dhahril
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D005533:Foot Dermatoses / Q000188:drug therapy*; D006229:Hand Dermatoses / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014009:Onychomycosis / Q000188:drug therapy*; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D015725:Fluconazole